Drugs / BI 767551
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04894474 | Jun 2021 → May 2022 | COVID-19 | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04822701 | Apr → Jul 2021 | COVID-19 | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 767551 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04894474 ↗ |
| Action | Inhibit | “Doctors check how BI 767551 reduces the amount of coronavirus.” NCT04822701 ↗ |
| Modality | Protein / enzyme biologic | “BI 767551 is an antibody against the coronavirus.” NCT04822701 ↗ |
| Route | Intravenous | “given as infusion into a vein” NCT04822701 ↗ |